Reducing systems biology to practice in pharmaceutical company research; Selected case studies

Advances in Experimental Medicine and Biology

Volumn 736, Issue , 2012, Pages 607-615

  Benson, N ^a   Cucurull Sanchez, L ^a   Demin, O ^b   Smirnov, S ^b   Van Der Graaf, P ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b Institute for Systems Biology   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GLYCOPROTEIN P; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; OPIATE AGONIST; RIBAVIRIN; SMALL INTERFERING RNA;

ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DRUG HALF LIFE; DRUG INDUSTRY; DRUG PENETRATION; DRUG TARGETING; HEPATITIS C; HUMAN; LIVER CELL; MATHEMATICAL MODEL; NONHUMAN; PHARMACOKINETIC PHARMACODYNAMIC MODELLING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SYSTEMS BIOLOGY;

BIOMEDICAL RESEARCH; BLOOD-BRAIN BARRIER; DRUG DESIGN; DRUG INDUSTRY; HEPATITIS C; HUMANS; INTERFERON-ALPHA; NF-KAPPA B; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; TECHNOLOGY TRANSFER;

EID: 84855980577     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-7210-1_36     Document Type: Article

References (26)

1. Munos B (2009) Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 8(12):959-968
2. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711-716. doi:10.1038/nrd1470
3. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL (2010) How to improve R& D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 9:203-214. doi:10.1038/nrd3078
4. Jensen ON (2004) Modification-specific proteomics: characterization of post-translational modifications by mass spectrometry. Curr Opin Chem Biol 8:33-41 (Pubitemid 38201475)
5. Kohl P, Crampin EJ, Quinn TA, Noble D (2010) Systems biology: an approach. Clin Pharmacol Ther 88(1):25-33. Epub 2010 June 9
6. Kohl P, Noble D (2009) Systems biology and the virtual physiological human. Mol Syst Biol 5:292. Epub 2009 July 28
7. Cohen A (2008) Pharmacokinetic and pharmacodynamic data to be derived from early-phase drug development-designing informative human pharmacological studies. Clin Pharmacokin 47:373-381 (Pubitemid 351685387)
8. Benson N, vander Graaf PH (2011) Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharm Res. 2011 Jul;28(7):1460-4. Epub 2011 May 11.
9. Swat MJ, Kie?basa SM, Polak S, Olivier B, Bruggeman FJ, Tulloch MQ, Snoep JL, Verhoeven AJ,Westerhoff HV (2011) What it takes to understand and cure a living system: computational systems biology and a systems biology-driven pharmacokinetics-pharmacodynamics platform. Interface Focus 1:16-23
10. Wist AD, Berger SI, Iyengar R (2009) Systems pharmacology and genome medicine: a future perspective. Genome Med 1(1):11
11. Ananiadou S, Kell DB, Tsujii J-i (2006) Text mining and its potential applications in systems biology. Trends Biotechnol 24(12):571-579 (Pubitemid 44762220)
12. Löscher W, Potschka H (2005) Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2(1):86-98 (Pubitemid 40128029)
13. Peletier LA, Benson N, van der Graaf PH (2010) Impact of protein binding on receptor occupancy: a two-compartment model. J Theor Biol 265(4):657-671. Epub 2010 June 2
14. Feng MR (2002) Assessment of blood-brain barrier penetration: in silico, in vitro and in vivo. Curr Drug Metab 3(6):647-657 (Pubitemid 35339328)
15. Ihekwaba AE, Broomhead DS, Grimley RL, Benson N, Kell DB (2004) Sensitivity analysis of parameters controlling oscillatory signalling in the NF-kappab pathway: the roles of IKK and ikappabalpha. Syst Biol 1(1):93-103
16. Dahari H, Shudo Emi, Cotler SJ, Layden TJ, Perelson AS (2009) Modeling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay. Antivir Ther 14(3):459-464
17. Dahari H, Lo A, Ribeiro RM, Perelson AS (2007) Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy. J Theor Biol 247(2):371-381. Epub 2007a, Mar 14 (Pubitemid 46863436)
18. Dahari H, Ribeiro RM, Perelson AS (2007) Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology 46(1):16-21 (Pubitemid 47171916)
19. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS (2004) Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 432(7019):922-924 (Pubitemid 40037156)
20. Snoeck E, Chanu P, Lavielle M, Jacqmin P, Jonsson EN, Jorga K, Goggin T, Grippo J, Jumbe NL, Frey NA (2010) Comprehensive hepatitis C viral kinetic model explaining cure. Clin Pharmacol Ther 87(6):706-713. Epub 2010 May 12
21. Maiwald T, Schneider A, Busch H, Sahle S, Gretz N, Weiss TS, Kummer U, Klingmüller U (2010) Combining theoretical analysis and experimental data generation reveals IRF9 as a crucial factor for accelerating interferon-induced early antiviral signalling. FEBS J 277(22):4741-4754
22. Igawa T, Tsunoda H, Kuramochi T, Sampei Z, Ishii S, Hattori K (2011) Engineering the variable region of therapeutic igg antibodies. MAbs. 3(3). Epub ahead of print
23. Meuleman P, Hesselgesser J, Paulson M, Vanwolleghem T, Desombere I, Reiser H, Leroux- Roels G (2008) Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 48(6):1761-1768
24. Finney, A., Hucka, M., Bornstein, B.J., Keating, S.M., Shapiro, B.E., Matthews, J., Kovitz, B.L., Schilstra, M.J., Funahashi, A., Doyle, J.C., Kitano, H. (2006). "Software Infrastructure for Effective Communication and Reuse of Computational Models". Systems Modeling in Cell Biology: From Concepts to Nuts and Bolts. MIT Press. pp. 369-378.
25. Rosenfeld S (2011) Mathematical descriptions of biochemical networks: stability, stochasticity, evolution. Progr Biophys Mol Biol 106(2):400-409. doi:10.1016/j.pbiomolbio.2011.03.003
26. Valeyev NV, Hundhausen C, Umezawa Y, Kotov NV, Williams G, Clop A, Ainali C, Ouzounis C, Tsoka S, Nestle FO (2010) A systems model for immune cell interactions unravels the mechanism of inflammation in human skin. PLoS Comput Biol 6(12):e1001024